S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
US Dollar Replaced By "Biden Bucks"? (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Biden's Plan to Confiscate Your Cash? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
US Dollar Replaced By "Biden Bucks"? (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Biden's Plan to Confiscate Your Cash? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
US Dollar Replaced By "Biden Bucks"? (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Biden's Plan to Confiscate Your Cash? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
US Dollar Replaced By "Biden Bucks"? (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
US Dollar Replaced By "Biden Bucks"? (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
Biden's Plan to Confiscate Your Cash? (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
NASDAQ:NBRV

Nabriva Therapeutics - NBRV Stock Forecast, Price & News

$0.18
0.00 (0.00%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.18
$0.19
50-Day Range
$0.17
$0.21
52-Week Range
$0.16
$1.40
Volume
521,515 shs
Average Volume
861,896 shs
Market Capitalization
$119.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Nabriva Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,011.1% Upside
$2.00 Price Target
Short Interest
Healthy
0.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.06mentions of Nabriva Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1,444 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.68) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

574th out of 1,119 stocks

Pharmaceutical Preparations Industry

280th out of 549 stocks

NBRV stock logo

About Nabriva Therapeutics (NASDAQ:NBRV) Stock

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Nabriva Therapeutics Stock Performance

NASDAQ:NBRV remained flat at $0.18 during trading hours on Thursday. 521,515 shares of the company's stock were exchanged, compared to its average volume of 635,928. The stock has a fifty day moving average of $0.19 and a 200-day moving average of $0.31. The firm has a market cap of $119.78 million, a price-to-earnings ratio of -0.22 and a beta of 1.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.01 and a current ratio of 2.81. Nabriva Therapeutics has a 52 week low of $0.16 and a 52 week high of $1.40.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Nabriva Therapeutics in a report on Thursday. They issued a "hold" rating on the stock.

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Stock News Headlines

Nabriva Inks Exclusive Distribution Agreement With Er-Kim
Nabriva Therapeutics's Earnings: A Preview
Nabriva Therapeutics Q4 2021 Earnings Preview
See More Headlines
Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Company Calendar

Last Earnings
5/06/2021
Today
8/19/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBRV
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+1,011.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-49,450,000.00
Net Margins
-131.91%
Pretax Margin
-130.68%

Debt

Sales & Book Value

Annual Sales
$28.90 million
Book Value
$0.05 per share

Miscellaneous

Free Float
654,600,000
Market Cap
$119.78 million
Optionable
Optionable
Beta
1.49

Key Executives

  • Mr. Theodore R. SchroederMr. Theodore R. Schroeder (Age 67)
    CEO & Director
    Comp: $929.45k
  • Dr. Steven P. Gelone Pharm. D (Age 54)
    Pres, COO & Director
    Comp: $931.67k
  • Dr. Colin Broom M.D. (Age 66)
    Director
    Comp: $39.78k
  • Mr. Daniel Dolan (Age 45)
    Chief Financial Officer
    Comp: $445.69k
  • Mr. J. Christopher Naftzger BAMr. J. Christopher Naftzger BA (Age 55)
    Esq., J.D., Gen. Counsel & Sec.
  • Ms. Jodi VanDerveer
    Sr. VP & Head of HR
  • Mr. Gary L. Sender (Age 60)
    Consultant
  • Dr. Christine J. Guico-Pabia M.B.A. (Age 59)
    M.D., M.P.H., Chief Medical Officer
  • Mr. Werner Heilmayer
    VP of CMC & IP













NBRV Stock - Frequently Asked Questions

Should I buy or sell Nabriva Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBRV shares.
View NBRV analyst ratings
or view top-rated stocks.

What is Nabriva Therapeutics' stock price forecast for 2022?

1 Wall Street research analysts have issued twelve-month price objectives for Nabriva Therapeutics' shares. Their NBRV share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 1,011.1% from the stock's current price.
View analysts price targets for NBRV
or view top-rated stocks among Wall Street analysts.

How have NBRV shares performed in 2022?

Nabriva Therapeutics' stock was trading at $0.5990 at the start of the year. Since then, NBRV stock has decreased by 69.9% and is now trading at $0.18.
View the best growth stocks for 2022 here
.

When is Nabriva Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our NBRV earnings forecast
.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.14. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 95.18% and a negative net margin of 131.91%.
Read the conference call transcript
.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, Gary Sender, J Christopher Naftzger, Stephen W Webster, Steven P Gelone, Theodore R Schroeder and Theodore R Schroeder.
View institutional ownership trends
.

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $0.18.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $119.78 million and generates $28.90 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639.

This page (NASDAQ:NBRV) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.